Osteoprotegerin, but not osteopontin, as a potential predictor of vascular calcification in normotensive subjects

Hypertension Research

Volumn 35, Issue 5, 2012, Pages 531-538

  Stpień, Ewa ^a   Fedak, Danuta ^a   Klimeczek, Piotr ^b   Wilkosz, Tadeusz ^b   Banyś, Robert Pawe ^b   Starzyk, Katarzyna ^c   Bazanek, Marta ^b   Pasowicz, Mieczysaw ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^c Swietokrzyskie Cardiology Center   (Poland)

Author keywords

Biomarkers; Bone remodeling; Multislice computed tomography; Synergistic diagnostics; Vascular calcification

Indexed keywords

CHOLESTEROL; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOPONTIN; OSTEOPROTEGERIN; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTICLE; BONE METABOLISM; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CORONARY ARTERY CALCIFICATION; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; FEMALE; FIBRINOGEN BLOOD LEVEL; GENDER; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; OBSERVATIONAL STUDY; PREDICTION; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

AGE FACTORS; AGED; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; OSTEOPONTIN; OSTEOPROTEGERIN; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; VASCULAR CALCIFICATION;

EID: 84860754839     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.231     Document Type: Article

References (38)

1. Waluś-Miarka M, Katra B, Fedak D, Czarnecka D, Miarka P, Woźniakiewicz E, Maecki M, Idzior-Waluś B. Osteoprotegerin is associated with markers of atherosclerosis and body fat mass in type 2 diabetes patients. Int J Cardiol 2011; 147: 335-336.
2. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106: 1192-1194.
3. Siepi D, Marchesi S, Vaudo G, Lupattelli G, Bagaglia F, Pirro M, Brozzetti M, Roscini AR, Mannarino E. Preclinical vascular damage in white postmenopausal women: the relevance of osteoprotegerin. Metabolism 2008; 57: 321-325.
4. Georgiadou P, Iliodromitis EK, Kolokathis F, Varounis C, Gizas V, Mavroidis M, Capetanaki Y, Boudoulas H, Kremastinos DT. Osteopontin as a novel prognostic marker in stable ischaemic heart disease: a 3-year follow-up study. Eur J Clin Invest 2010; 40: 288-293.
5. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999; 96: 3540-3545.
6. Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, Kido S, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004; 104: 2484-2491.
7. Fitzpatrick LA, Severson A, Edwards WD, Ingram RT. Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis. J Clin Invest 1994; 94: 1597-1604.
8. Tamura A, Shingai M, Aso N, Hazuku T, Nasu M. Osteopontin is released from the heart into the coronary circulation in patients with a previous anterior wall myocardial infarction. Circ J 2003; 67: 742-744.
9. Stepień E, Wypasek E, Stopyra K, Konieczyń ska M, Przybyo M, Pasowicz M. Increased levels of bone remodeling biomarkers (osteoprotegerin and steopontin) in hypertensive individuals. Clin Biochem 2011; 44: 826-831.
10. Anand DV, Lim E, Darko D, Bassett P, Hopkins D, Lipkin D, Corder R, Lahiri A. Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers. J Am Coll Cardiol 2007; 50: 2218-2225.
11. Sumino H, Ichikawa S, Kasama S, Takahashi T, Sakamoto H, Kumakura H, Takayama Y, Kanda T, Murakami M, Kurabayashi M. Relationship between carotid atherosclerosis and lumbar spine bone mineral density in postmenopausal women. Hypertens Res 2008; 31: 1191-1197.
12. Mikami S, Hamano T, Fujii N, Nagasawa Y, Isaka Y, Moriyama T, Matsuhisa M, Ito T, Imai E, Hori M. Serum osteoprotegerin as a screening tool for coronary artery calcification score in diabetic pre-dialysis patients. Hypertens Res 2008; 31: 1163-1170.
13. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006; 47: 1850-1857.
14. Miszalski-Jamka T, Klimeczek P, Banyś R, Krupiński M, Nycz K, Bury K, Lada M, Pelberg R, Kereiakes D, Mazur W. The composition and extent of coronary artery plaque detected by multislice computed tomographic angiography provides incremental prognostic value in patients with suspected coronary artery disease. Int J Cardiovasc Imaging 2011 (in press; DOI:10.1007/s10554-011-9799-0).
15. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109: 2175-2180.
16. Jono S, Otsuki S, Higashikuni Y, Shioi A, Mori K, Hara K, Hashimoto H, Ikari Y. Serum osteoprotegerin levels and long-term prognosis in subjects with stable coronary artery disease. J Thromb Haemost 2010; 8: 1170-1175.
17. Dao HH, Essalihi R, Bouvet C, Moreau P. Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension. Cardiovasc Res 2005; 66: 307-317.
18. van Popele NM, Mattace-Raso FU, Vliegenthart R, Grobbee DE, Asmar R, van der Kuip DA, Hofman A, de Feijter PJ, Oudkerk M, Witteman JC. Aortic stiffness is associated with atherosclerosis of the coronary arteries in older adults: the Rotterdam Study. J Hypertens 2006; 24: 2371-2376.
19. Matsui Y, Jia N, Okamoto H, Kon S, Onozuka H, Akino M, Liu L, Morimoto J, Rittling SR, Denhardt D, Kitabatake A, Uede T. Role of Osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension 2004; 43: 1195-1201.
20. Golledge J, McCann M, Mangan S, Lam A, Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 2004; 35: 1636-1641.
21. Xie Z, Singh M, Singh K. Osteopontin modulates myocardial hypertrophy in response to chronic pressure overload in mice. Hypertension 2004; 44: 826-831.
22. Renault MA, Jalvy S, Potier M, Belloc I, Genot E, Dekker LV, Desgranges C, Gadeau AP. UTP induces osteopontin expression through a coordinate action of NFkappaB, activator protein-1, and upstream stimulatory factor in arterial smooth muscle cells. J Biol Chem 2005; 280: 2708-2713.
23. Lorenzen J, Krämer R, Kliem V, Bode-Boeger SM, Veldink H, Haller H, Fliser D, Kielstein JT. Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease. Eur J Clin Invest 2010; 40: 294-300.
24. Kiefer FW, Zeyda M, Gollinger K, Pfau B, Neuhofer A, Weichhart T, Säemann MD, Geyeregger R, Schlederer M, Kenner L, Stulnig TM. Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes 2010; 59: 935-946.
25. Nilsson-Berglund LM, Zetterqvist AV, Nilsson-Ohman J, Sigvardsson M, González Bosc LV, Smith ML, Salehi A, Agardh E, Fredrikson GN, Agardh CD, Nilsson J, Wamhoff BR, Hultga°rdh-Nilsson A, Gomez MF. Nuclear factor of activated T cells regulates osteopontin expression in arterial smooth muscle in response to diabetes-induced hyperglycemia. Arterioscler Thromb Vasc Biol 2010; 30: 218-224.
26. Chino T, Draves KE, Clark EA. Regulation of dendritic cell survival and cytokine production by osteoprotegerin. J Leukoc Biol 2009; 86: 933-940.
27. Kim SM, Lee J, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol (Oxf) 2005; 63: 594-598.
28. Ueland T, Wilson SG, Amirul Islam FM, Mullin B, Devine A, Bollerslev J, Zhu K, Prince RL. A cohort study of the effects of serum OPG and OPG gene polymorphisms on cardiovascular mortality in elderly women. Clin Endocrinol (Oxf) 2009; 71: 828-833.
29. Semb AG, Ueland T, Aukrust P, Wareham NJ, Luben R, Gullestad L, Kastelein JJ, Khaw KT, Boekholdt SM. Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. Arterioscler Thromb Vasc Biol 2009; 29: 975-980.
30. van Woudenbergh GJ, Vliegenthart R, van Rooij FJ, Hofman A, Oudkerk M, Witteman JC, Geleijnse JM. Coffee consumption and coronary calcification: the Rotterdam Coronary Calcification Study. Arterioscler Thromb Vasc Biol 2008; 28: 1018-1023.
31. Tlaka M, Pasowicz M, Kolasa-Trela R, Konieczyń ska M, Klimeczek P, Misiak M, Wilkosz T. Self-rated health as a predictor of subclinical atherosclerosis measured by CCS among asymptomatic individuals (Abstract). World Congress of Cardiology, Barcelona, Spain, Sep 02-06. Eur Heart J 2006; 27: S387.
32. El Barzouhi A, Elias-Smale S, Dehghan A, Vliegenthart-Proença R, Oudkerk M, Hofman A, Witteman JC. Renal function is related to severity of coronary artery calcification in elderly persons: the Rotterdam study. PLoS One 2011; 6: e16738.
33. Sanada M, Taguchi A, Higashi Y, Tsuda M, Kodama I, Yoshizumi M, Ohama K. Forearm endothelial function and bone mineral loss in postmenopausal women. Atherosclerosis 2004; 176: 387-392.
34. Sumino H, Ichikawa S, Kasama S, Takahashi T, Kumakura H, Takayama Y, Kanda T, Sakamaki T, Kurabayashi M. Elevated arterial stiffness in postmenopausal women with osteoporosis. Maturitas 2006; 55: 212-218.
35. Jaffe AS. Key issues in the developing synergism between cardiovascular imaging and biomarkers. Clin Chem 2008; 54: 1432-1442.
36. Pasowicz M, Starzyk K, Klimeczek P, Stepien E, Tracz W. Comparative study of the elevated hs-C-reactive protein and lipid profile, the selected markers of atherosclerotic inflammation and coronary artery calcifications in the middle-aged men with no artery disease or diabetes. (Abstract) Congress of the European Society of Cardiology, Vienna, Austria, Aug 30-Sep 03. Eur Heart J 2003; 24: S574.
37. Gottlieb I, Miller JM, Arbab-Zadeh A, Dewey M, Clouse ME, Sara L, Niinuma H, Bush DE, Paul N, Vavere AL, Texter J, Brinker J, Lima JA, Rochitte CE. The absence of coronary calcification does not exclude obstructive coronary artery disease or the need for revascularization in patients referred for conventional coronary angiography. J Am Coll Cardiol 2010; 55: 627-634.
38. Yang Q, Lu S, Chen Y, Song X, Jin Z, Yuan F, Li H, Zhou Y, Chen F, Huo Y. Plasma osteoprotegerin levels and long-term prognosis in patients with intermediate coronary artery lesions. Clin Cardiol 2011; 34: 447-453.